Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Representatives Grill Shuren, Advance SOFTWARE Act

This article was originally published in The Gray Sheet

Executive Summary

Tennessee Republican Rep. Marsha Blackburn’s SOFTWARE Act advanced to the Health Subcommittee of the House Energy & Commerce Committee Nov. 19, where representatives grilled CDRH Director Jeffrey Shuren on health information technology regulation.

You may also be interested in...



McKesson Recall Dovetails With Broader Health IT Reg Debate

One of McKesson Corp.’s clinical decision support software products underwent a class I recall, but it may not have been subject to this type of FDA enforcement if legislation currently under consideration in Congress was law.

Health IT Reg Bill Sparks Debate; AdvaMed Tries To Address “Technical Concerns”

The PROTECT Act, introduced by Sens. Fischer, R-Neb., and King, I-Maine, earlier this month to restrict FDA oversight of software tools has already triggered some high-profile discussion, with a USA Today op-ed from sponsors and an opposition letter from consumer groups. AdvaMed, meanwhile, is playing more of a behind-the-scene role.

Health IT Deregulation Bill Introduced In Senate, With Powerful Industry Backers

The PROTECT Act, which attempts to respond to some criticisms of the House SOFTWARE Act, aims to restrict FDA’s oversight of health information technology. It is backed by IBM and Verizon, among others.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT032619

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel